Nav: Home

Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy

December 13, 2016

Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, CT, USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.

Triple negative breast cancer is so called because it lacks molecular characteristics that are associated with response to modern targeted treatments. Hatzis and colleagues selected individual tumors from patients who had exhibited either good or poor sensitivity to cytotoxic chemotherapy, and characterized 29 cases of the disease by whole exome sequencing, with validation in further groups of patients. Patients with a newly-defined "BRCA deficient" subtype experienced better survival with chemotherapy, and had a higher burden of mutations and neoantigens that could be targeted by the immune system. Based on these findings, the authors suggest that immunotherapies might be tested in patients with BRCA deficient, triple negative breast cancer.

In a commissioned Perspective article, Mack Su and David Fisher of Massachusetts General Hospital, Boston, MA, USA discuss developments in cancer immunotherapy, an area which has had a long history. During the past decade there have been notable advances in the treatment of melanoma, an aggressive tumor type which is increasing in incidence in some populations. Alongside development of drugs which target the BRAF mutations that are common in melanoma, therapies have been discovered that stimulate the immune response to tumors--blocking so-called checkpoints, or inhibitors of the immune response. Su and Fisher describe the potential for use of different combinations of immune and targeted therapies and conclude that, as new immunotherapies are developed and tested in different tumor types, "deeper mechanistic insight will be required to inform clinical decisions."
-end-
Research Article

Funding:

This work was supported in part by grants from the Breast Cancer Research Foundation to CH, LP and WFS and from the Lion Heart Fund for Cancer Research to CH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests:

All authors have read the journal's policy and the authors of this manuscript have the following competing interests: WFS reports stock and intellectual property in Nuvera Biosciences, Inc.

Citation:

Jiang T, Shi W, Wali VB, Pongor LS, Li C, Lau R, et al. (2016) Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. PLoS Med 13(12): e1002193. doi:10.1371/journal.pmed.1002193

Author Affiliations:

Department of Medicine, Yale School of Medicine, Yale University, New Haven, Connecticut, United States of America
MTA TTK Lendulet Cancer Biomarker Research Group, Research Center for Natural Sciences,
Budapest, Hungary
2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary
Department of Genetics, Yale School of Medicine, Yale University, New Haven, Connecticut, United States of America
Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
Yale Cancer Center, New Haven, Connecticut, United States of America

IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER:

http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002193

Perspective Article

Funding:

The authors gratefully acknowledge support from NIH grants 5P01 CA163222, 5R01 AR043369-19, and T32GM007753, and grants from the Melanoma Research Alliance, and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests:

The authors have declared that no competing interests exist.

Citation:

Su MY, Fisher DE (2016) Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. PLoS Med 13(12): e1002196. doi:10.1371/journal.pmed.1002196

Author Affiliations:

Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER:

http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002196

PLOS

Related Chemotherapy Articles:

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.
Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.
Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.
A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.
Chemotherapy or not?
Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how 'smart' diagnostic-imaging machines identify cancers -- and uncovering clues outside the tumor to tell whether a patient will respond well to chemotherapy.
Researchers use radiomics to predict who will benefit from chemotherapy
Using data from computed tomography (CT) images, researchers may be able to predict which lung cancer patients will respond to chemotherapy, according to a new study.
How drugs can minimize the side effects of chemotherapy
Researchers at the University of Zurich have determined the three-dimensional structure of the receptor that causes nausea and vomiting as a result of cancer chemotherapy.
Capturing chemotherapy drugs before they can cause side effects
Although chemotherapy can kill cancer cells very effectively, healthy cells also suffer.
Tumors backfire on chemotherapy
Chemotherapy is an effective treatment for breast cancer, yet some patients develop metastasis in spite of it.
Turbo-charging chemotherapy for lung cancer
Lung cancer, the leading cause of cancer death, is often treated with chemotherapy - but its effectiveness is limited by cancer cell resistance and by a harmful side effect: kidney damage.
More Chemotherapy News and Chemotherapy Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.